University of Leipzig Heart Center
|
|
- Dayna Willis
- 6 years ago
- Views:
Transcription
1 Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock Holger Thiele, MD Uwe Zeymer, MD; Franz-Josef Neumann, MD; Miroslaw Ferenc, MD; Hans-Georg Olbrich, MD; Jörg Hausleiter, MD; Gert Richardt, MD; Marcus Hennersdorf, MD; Klaus Empen, MD; Georg Fuernau, MD; Steffen Desch, MD; Ingo Eitel, MD; Rainer Hambrecht, MD; Jörg Fuhrmann, MD; Michael Böhm, MD; Henning Ebelt, MD; Steffen Schneider, PhD; Gerhard Schuler, MD; Karl Werdan, MD on behalf of the IABP-SHOCK II Trial Investigators University of Leipzig Heart Center
2 Disclosures Funding: German Research Foundation German Heart Research Foundation German Cardiac Society Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte University of Leipzig Heart Center Unrestricted grant by: Maquet Cardiopulmonary AG, Hirrlingen, Germany Teleflex Medical, Everett, MA, USA Potential Conflict of Interest: Research Funding: Terumo, Lilly, Maquet Cardiovascular, Teleflex Medical Consulting: Maquet Cardiovascular, Lilly Speaker Honoraria: Lilly, Astra Zeneca, Daiichi Sankyo, Boehringer Ingelheim, Maquet Cardiovascular, Medicines Company
3 Background IABP in Cardiogenic Shock History: 1962 Animal studies Moulopoulos et al. Am Heart J 1962;63: First clinical description in shock Kantrowitz et al. JAMA 1968;203: Hemodynamic effects in shock, Mortality unchanged Scheidt et al. NEJM 1973;288: > 40 years > 1 Million patients treated, low complication rate, Benchmark registry Ferguson et al. JACC 2001;38:
4 Background Guidelines Van de Werf et al. Eur Heart J 2008;29: Wijns et al. Eur Heart J 2010;31: Antman et al. Circulation 2004;110: IABP in AMI complicated by cardiogenic shock ESC Class IC ACC/AHA Class IB
5 Background Mortality IABP vs no IABP - Metaanalysis Trial IABP n/n No IABP n/n 30-day mortality Risk difference No reperfusion Moloupoulos 24/34 15/15 Overall 24/34 15/ (-0.47 to -0.12) Thrombolysis Stomel 28/51 10/13 Kovack 10/27 13/19 Bengtson Waksman 48/99 11/20 58/101 17/21 GUSTO-1 SHOCK registry 30/62 220/ / /417 NRMI-2 TT 1068/ /3501 Overall 1415/ / (-0.20 to -0.16) Primary PCI NRMI-2 PCI AMC CS 956/ / /955 26/93 Overall 1049/ / (0.03 to 0.10) Overall 2488/ / (-0.13 to -0.09) IABP better No IABP better Sjauw et al. Eur Heart J 2009;30:
6 Methods Study Sites and Organisation DSMB: Kurt Huber Ferenc Follath Bernhard Maisch Johannes Haerting Steering committee: Holger Thiele Karl Werdan Uwe Zeymer Gerhard Schuler Support + Patronage:
7 Results Trial Flow and Treatment 790 patients with AMI and cardiogenic shock screened 600 randomized 190 excluded because of exclusion criteria - 60 no informed consent - 47 resuscitation >30 minutes - 19 shock duration >12 hours - 18 severe peripheral artery disease - 14 participation in another trial - 13 no intrinsic heart activity - 9 mechanical complication - 3 shock of other cause - 3 comorbidity with life expectancy <6 months - 2 severe cerebral deficit - 2 age >90 years 301 randomized to IABP 288 received IABP 13 did not receive IABP - 10 died before IABP insertion - 3 protocol violation (2 not suitable for revascularization, 1 serious kinking) Allocation 299 randomized to control 269 received control therapy 30 cross-over to IABP (22 first day, 8 day 1-8) - 4 mechanical complications - 25 protocol violation - 1 unknown reason 301 intended early revascularization 287 primary PCI 3 primary CABG 11 no revascularization - 3 not suitable for revascularization - 4 coronary artery disease with no identifiable culprit lesion - 4 no coronary artery disease Revascularization 299 intended early revascularization 288 primary PCI 3 primary CABG 8 no revascularization - 1 not suitable for revascularization - 2 coronary artery disease with no identifiable culprit lesion - 5 no coronary artery disease 300 with 30-day follow-up - 1 lost to follow-up 300 primary endpoint analysis Follow-up Primary endpoint analysis 298 with 30-day follow-up - 1 withdrew informed consent 298 primary endpoint analysis
8 Results Primary Study Endpoint (30-Day Mortality) Mortality (%) Control IABP 41.3% 39.7% P=0.92 by log-rank test Relative risk 0.96; 95% CI ; P=0.69 by Chi 2 -Test Time after Randomization (Days)
9 Results Subgroups (30-Day Mortality) Baseline Variable N 30-Day Mortality (%) IABP Control Relative Risk (95% CI) P-Value for Interaction Female Male ( ) 0.92 ( ) 0.61 Age <50 years Age years Age >75 years ( ) 0.95 ( ) 1.07 ( ) 0.09 Diabetes No diabetes ( ) 0.96 ( ) 0.82 Hypertension No hypertension ( ) 0.67 ( ) 0.05 STEMI/LBBB NSTEMI ( ) 0.98 ( ) 0.76 Anterior STEMI Non-anterior STEMI ( ) 1.16 ( ) 0.14 Previous infarction No previous infarction ( ) 0.86 ( ) 0.04 Hypothermia No hypothermia ( ) 0.89 ( ) 0.31 Blood pressure <80 mmhg Blood pressure 80 mmhg ( ) 0.92 ( ) IABP better Control better
10 Summary + Conclusions IABP support in cardiogenic shock is safe without significant inherent complications. However, IABP support did not reduce 30-day mortality in this large, randomized, multicenter trial in cardiogenic shock patients complicating myocardial infarction undergoing early revascularization. The primary study endpoint results are supported by a lack of benefit in secondary endpoints.
11
A Future for the IABP in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany
A Future for the in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany Disclosures Funding: German Research Foundation German Heart Research
More informationUniversity of Leipzig Heart Center
Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock Holger
More informationUniversity of Leipzig Heart Center
Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock Holger
More informationMild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction the Randomized SHOCK-COOL Trial
Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction the Randomized SHOCK-COOL Trial Georg Fuernau, Johannes Beck, Steffen Desch, Ingo Eitel, Christian Jung, Sandra Erbs, Norman Mangner,
More informationCULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock. Holger Thiele, MD on behalf of the CULPRIT-SHOCK Investigators
CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock Holger Thiele, MD on behalf of the CULPRIT-SHOCK Investigators Disclosure Statement of Financial Interest Within the past 12 months,
More informationIntraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock
original article Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock Holger Thiele, M.D., Uwe Zeymer, M.D., Franz-Josef Neumann, M.D., Miroslaw Ferenc, M.D., Hans-Georg Olbrich,
More informationIABP SHOCK II trial:
IABP SHOCK II trial: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic
More informationThe Case for Multivessel Revascularization in Shock
The Case for Multivessel Revascularization in Shock Emmanouil S. Brilakis, MD, PhD Minneapolis Heart Institute 9.37 9.49 am Disclosures Consulting/speaker honoraria: Abbott Vascular, American Heart Association
More informationIntracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention
Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention Cardiac Magnetic Resonance Substudy of the AIDA STEMI trial Holger Thiele, MD; Jochen
More informationIntraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
More informationCardiogenic shock: Current management
Cardiogenic shock: Current management Janine Pöss Universitätsklinikum des Saarlandes Klinik für Innere Medizin III Kardiologie, Angiologie und internistische Intensivmedizin Homburg/Saar I have nothing
More informationSOLVE-TAV. Holger Thiele, MD on behalf of the SOLVE-TAVI Investigators
SOLVE-TAV A 2x2 Randomized Trial of Self-Expandable vs Balloon-Expandable Valves and General vs Local Anesthesia in Patients Undergoing Transcatheter Aortic Valve Implantation Holger Thiele, MD on behalf
More informationAssist Devices in STEMI- Intra-aortic Balloon Pump
Assist Devices in STEMI- Intra-aortic Balloon Pump Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center Athens, Greece Cardiogenic shock 5-10% of pts after a heart attack 60000-70000 pts in Europe/year
More informationManagement of Cardiogenic shock. Prof. Christian JM Vrints
Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease
More informationPrognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction
Prognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction Holger Thiele, MD; Konrad Kubusch, BSc; Steffen Desch,
More informationPost resuscitation care and role of urgent angiography after cardiac arrest. Georg Fuernau Luebeck
Post resuscitation care and role of urgent angiography after cardiac arrest Georg Fuernau Luebeck The journey CPR and guidelines European Resuscitation Council American Heart Association International
More informationST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary Conflicts of interest Advisory Boards Cordis Boston Scientific
More informationCardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands
Cardiogenic Shock Dr. JPS Henriques Academic Medical Center University of Amsterdam The Netherlands Conflict of interest disclosure Research grant Abbott Vascular Research grant Abiomed Inc. Global Impella
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationHow to do Primary Angioplasty. - Patients with Cardiogenic Shock
How to do Primary Angioplasty - Patients with Cardiogenic Shock Advanced Cardiovascular Intervention 2011 Dan Blackman Leeds General Infirmary MY CONFLICTS OF INTEREST ARE: Research Grants Medicines Company
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationWhy we need a consensus document on cardiogenic shock? ACCA Masterclass 2017
Why we need a consensus document on cardiogenic shock? ACCA Masterclass 2017 Holger Thiele Cardiogenic Shock STEMI Guidelines Steg et al. Eur Heart J.2012;33:2569-2619 Cardiogenic Shock CHF Guidelines
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationSTEMI Linee guida ESC Maddalena Lettino, Italy
STEMI Linee guida ESC 2017 Maddalena Lettino, Italy Disclosure Speaker fee: Aspen, Astra Zeneca, BMS, Boehringer, Eli Lilly, DaichiiSankio, Bayer, Pfizer, Sanofi Advisory board member: Astra Zeneca, Eli
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationΟξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση. Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας
Οξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας ACUTE HEART FAILURE AND CAD: ACS / LV ischaemic dysfunction Mechanical complications
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationNew Horizons in Cardiogenic Shock. Timothy D. Henry, MD Director of Cardiology Cedars-Sinai Heart Institute
New Horizons in Cardiogenic Shock Timothy D. Henry, MD Director of Cardiology Cedars-Sinai Heart Institute AMI Shock Mortality Unchanged in > 20 years 74355 US AMI/CGS cases per year 1,2 78954 78500 79823
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationPercutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.
UvA-DARE (Digital Academic Repository) Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. Link to publication Citation for published version
More informationMechanical circulatory support in cardiogenic shock
European Heart Journal (2014) 35, 156 167 doi:10.1093/eurheartj/eht248 REVIEW Novel devices Mechanical circulatory support in cardiogenic shock Karl Werdan 1 *, Stephan Gielen 1, Henning Ebelt 1, and Judith
More informationManagement of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationRationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
More informationXiao-yun Zheng *, Yi Wang, Yi Chen, Xi Wang, Lei Chen, Jun Li and Zhi-gang Zheng
Zheng et al. BMC Cardiovascular Disorders (2016) 16:148 DOI 10.1186/s12872-016-0323-2 RESEARCH ARTICLE Open Access The effectiveness of intra-aortic balloon pump for myocardial infarction in patients with
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationSHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?
SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? Kurt Huber, MD 3 Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria Disclosures DISCLOSURE
More informationNews the. Methods Data collection. The NCDR is a national registry of patients undergoing diagnostic cardiac catheterizations
Journal of the American College of Cardiology Vol. 52, No. 20, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.017
More informationClinical experience with the intra-aortic balloon pump
Expert Opinion Intra-aortic Balloon Pump Trials Questions, Answers, and Unresolved Issues Divaka Perera, MD, FRCP; Matthew Lumley, BSc, MRCP; Nico Pijls, MD, PhD; Manesh R. Patel, MD Clinical experience
More informationFFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators
FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of
More informationMODULE 2 THE CLINICAL ENIGMA: RANDOMIZED TRIALS vs CLINICAL PRACTICE. Nico H. J. Pijls, MD, PhD Catharina Hospital Eindhoven The Netherlands
MODULE 2 THE CLINICAL ENIGMA: RANDOMIZED TRIALS vs CLINICAL PRACTICE Nico H. J. Pijls, MD, PhD Catharina Hospital Eindhoven The Netherlands Disclosure All presenters have a speaker agreement with Maquet
More informationControversies In STEMI Management
Controversies In STEMI Management Professor Mohamed Sobhy, MD, FACC, FESC Professor of Cardiology Department, Alexandria University - Egypt Past President of the Egyptian Society of Cardiology President
More informationTrends in reperfusion therapy of STEMI patients in Belgium for the period
214 Trends in reperfusion therapy of STEMI patients in Belgium for the period 27-213 Prof dr M Claeys National Coordinator STEMI registry 12-5-214 Background The current guidelines for the management of
More informationPercutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.
UvA-DARE (Digital Academic Repository) Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. Link to publication Citation for published version
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationNew Insights on Reperfusion Choices Implications of STREAM. Paul W Armstrong MD
New Insights on Reperfusion Choices Implications of STREAM ESC STEMI Satellite Symposium August 31 2014 Aligning Optimal Care to Time Place and Person Paul W Armstrong MD Disclosure Statement Paul W. Armstrong
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationThe Strategic Reperfusion Early After STEMI study Implications for clinical practice
The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional
More informationSTEMI and Cardiogenic Shock. The rules and solution. Dave Kettles St Dominics and Frere Hospitals East London ZA
STEMI and Cardiogenic Shock. The rules and solution Dave Kettles St Dominics and Frere Hospitals East London ZA Definitions: Shock is a life threatening, but initially reversible state of cellular and
More informationOut-of-hospital Cardiac Arrest. Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland
Out-of-hospital Cardiac Arrest Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland Conflict of Interest I have no conflict of interest to disclose regarding this presentation.
More informationSTEMI Care 2014 at the Crossroads: Taking the right road
STEMI Care 2014 at the Crossroads: Taking the right road Robert C. Welsh, MD, FRCPC, FESC, FAHA, FACC Professor of Medicine Vice President, The Canadian Association of Interventional Cardiology Director,
More informationAcute Myocardial Infarction Complicated by Cardiogenic Shock
Acute Myocardial Infarction Complicated by Cardiogenic Shock Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional
More informationIntroduction to Acute Mechanical Circulatory Support
Introduction to Acute Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive
More informationJudith Walsh, MD, MPH. Professor of Medicine. Division of General Internal Medicine. Department of Medicine. University of California San Francisco
TITLE: Intra-aortic aortic Balloon Pump for Treatment of Cardiogenic Shock AUTHOR: Judith Walsh, MD, MPH Professor of Medicine Division of General Internal Medicine Department of Medicine University of
More informationTed Feldman, M.D., MSCAI FACC FESC
Support Technologies and High Risk Intervention Patient Selection: When Not to Use Them Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas December 7-10 th, 2014 Ted
More informationPharmaco-Invasive Approach for STEMI
Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),
More informationPHARMACO-INVASIVE STRATEGY COMPARED WITH PPCI: DESIGN AND MAIN OUTCOMES OF THE STREAM TRIAL
PHARMACO-INVASIVE STRATEGY COMPARED WITH PPCI: DESIGN AND MAIN OUTCOMES OF THE STREAM TRIAL Frans Van de Werf Leuven, Belgium Disclosures Study grant from Boehringer Ingelheim to perform the STREAM trial,
More informationFuernau et al. Critical Care (2014) 18:713 DOI /s
Fuernau et al. Critical Care (2014) 18:713 DOI 10.1186/s13054-014-0713-8 RESEARCH Open Access Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy
More informationTransfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem
Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927
More informationLi Xu 1, MD, Hao Sun 1, MD, Le-Feng Wang 1, MD, Xin-Chun Yang 1, MD, Kui-Bao Li 1, MD, Da-Peng Zhang 1, MD, Hong-Shi Wang 1, MD, Wei-Ming Li 1, MD
Singapore Med J 2016; 57(7): 396-400 doi: 10.11622/smedj.2016121 Long-term prognosis of patients with acute myocardial infarction due to unprotected left main coronary artery disease: a single-centre experience
More informationImpella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials
Accepted Manuscript Impella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials Dagmar M. Ouweneel, MSc, Erlend Eriksen, MD, Melchior Seyfarth,
More informationLow cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ
Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ Low cardiac output/cardiogenic Shock State of end-organ hypoperfusion due to cardiac failure.
More informationPrimary Percutaneous Coronary Intervention
The big 5 in PCI Primary Percutaneous Coronary Intervention W. Wijns (Aalst, BE) Disclosures Consulting Fees: on my behalf go to the Cardiovascular Research Center Aalst Contracted Research between the
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationMechanical circulatory support in acute cardiogenic shock Mubashar H Khan, Brian J Corbett and Steven M Hollenberg*
Published: 01 October 2014 2014 Faculty of 1000 Ltd Mechanical circulatory support in acute cardiogenic shock Mubashar H Khan, Brian J Corbett and Steven M Hollenberg* Address: Cooper University Hospital,
More informationPatients in whom PCI is preferred over CABG _ Aleksander Ernst Clinical Hospital Center Zagreb University of Zagreb School of Medicine Zagreb, CROATIA
3rd Dubrovnik Cardiology Highlights An ESC Update Programme in Cardiology 26.09.-29.09.2013, Hotel Excelsior, Dubrovnik, Croatia Patients in whom PCI is preferred over CABG _ Aleksander Ernst Clinical
More informationMode of admission and its effect on quality indicators in Belgian STEMI patients
2015 Mode of admission and its effect on quality indicators in Belgian STEMI patients Prof dr M Claeys National Coordinator STEMI registry 29-6-2015 Background The current guidelines for the management
More informationJoo-Yong Hahn, MD/PhD
Sungkyunkwan University School of Medicine Joo-Yong Hahn, MD/PhD Heart Vascular Stork Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Grant support Korean Society of Interventional
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationReperfusion Strategy in Europe: Temporal Trends in Performance Measures for Reperfusion Therapy in ST Elevation Myocardial Infarction
Reperfusion Strategy in Europe: Temporal Trends in Performance Measures for Reperfusion Therapy in ST Elevation Myocardial Infarction F. Schiele 1, M. Hochadel 2, M. Tubaro 3, N. Meneveau 1, W. Wojakowski
More informationWhat is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN
What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN October 2011 Part 2 Summary of newer antithrombotic and antiplatelet agents in STEMI Role of thrombectomy in PPCI
More informationMANAGEMENT OF CARDIOGENIC SHOCK
MANAGEMENT OF CARDIOGENIC SHOCK CASE PRESENTATION 37 year old Dutch female No known coronary artery disease risk factors 1 week post partum at time of presentation (G3P3) after an uncomplicated normal
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More informationACC Rockies New Role For An Old Friend: Contemporary Insights From The ECG
ACC Rockies 2012 New Role For An Old Friend: Contemporary Insights From The ECG Paul W. Armstrong, MD Monday March 12 2012 2012 Disclosure Statement Paul W. Armstrong MD Details available @ http://www.vigour.ualberta.ca
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM The Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial November 218 Recovering Hearts. Saving Lives. LEGAL DISCLAIMERS This presentation includes select slides
More informationPresented by Prof David Erlinge, MD, PhD, On behalf of the RAPID MI-ICE Investigators
Cold saline and endovascular cooling induces rapid hypothermia before reperfusion in STEMI patients treated with primary PCI, is safe and reduces infarct size with a scattered myocardial salvage Presented
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationThe development of cardiogenic shock portends an extremely poor prognosis. Cardiogenic Shock: A Lethal Complication of Acute Myocardial Infarction
TREATMENT UPDATE Cardiogenic Shock: A Lethal Complication of Acute Myocardial Infarction David R. Holmes, Jr, MD Mayo Graduate School of Medicine, Mayo Clinic, Rochester, MN Cardiogenic shock is a serious
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) Disclosures Investigator Initiated Trial: NCT00828087. Unrestricted grant from Abbott to the Spanish Heart Foundation.
More informationCritics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS
Critics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS STEMI Stuff New or Recurrent MI s in U.S.: 865,000 Acute STEMI s: 500,000 Sooner
More informationAcute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT
Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita
More informationDespite improvements in STEMI care. The 6 month mortality remains high ~10% 1. Intra-aortic balloon counterpulsation
Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: The CRISP AMI Randomized Trial Manesh R. Patel, MD, Richard W. Smalling, MD,
More informationESC 2012: Klinisch relevante Neuigkeiten beim ACS
Kardiologie-Kreis KH Barmherzige Schwestern Linz, 2.10.2012 ESC 2012: Klinisch relevante Neuigkeiten beim ACS 30 Minuten Priv.- Doz. Dr. Hannes Alber REHA ZENTRUM MÜNSTER UNIV.- KLINIK f. INNERE MED. III
More informationACQUIRED CARDIOVASCULAR DISEASE
ACQUIRED CARDIOVASCULAR DISEASE Coronary artery bypass graft surgery provides better survival in patients with acute coronary syndrome or ST-segment elevation myocardial infarction experiencing cardiogenic
More informationAdvances in Interventional Cardiology
Advances in Interventional Cardiology Intra-Aortic Balloon Pump for High-Risk Percutaneous Coronary Intervention Tiffany Patterson, MBBS, BSc, MRCP; Divaka Perera, MB BChir, MD, FRCP; Simon R. Redwood,
More informationCardiogenic Shock and Initiatives to Reduce Mortality
Cardiogenic Shock and Initiatives to Reduce Mortality Tanveer Rab, MD, FACC William O Neill, MD, FACC Perwaiz Meraj, MD, FACC Alex Truesdell, MD, FACC The Golden Hours? 50% dead within 10 hours Overall
More informationOne-Year Outcomes after PCI Strategies in Cardiogenic Shock
Original Article One-Year Outcomes after PCI Strategies in Cardiogenic Shock H. Thiele, I. Akin, M. Sandri, S. de Waha Thiele, R. Meyer Saraei, G. Fuernau, I. Eitel, P. Nordbeck, T. Geisler, U. Landmesser,
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationUnprotected Left Main Coronary Disease and ST-Segment Elevation Myocardial Infarction
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 8, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.06.005 STATE-OF-THE-ART
More informationRegistry and benchmarking as tool for Quality assessment in STEMI patients
Registry and benchmarking as tool for Quality assessment in STEMI patients Belgian Interdisciplinary Working Group on Acute Cardiology (BIWAC) College of Cardiology April 2007 Background Reperfusion strategy
More informationM/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #
Acute Coronary Syndrome - Case Review - Young-Guk Ko, MD Yonsei Cardiovascular Center Yonsei University College of Medicine Case 1 M/39 #4306212 CC D : Severe squeezing chest pain : 4 hours, aggravated
More informationDepartment of Medicine III, Martin Luther-University Halle, Germany b. Unità Operativa di Cardiologia, Ospedale Maggiore, Bologna, Italy c
Comparison of CHADS 2 -Score with CHA 2 DS 2 VASc-Score in a prospective multicenter registry on patients with atrial fibrillation undergoing coronary artery stenting -First results from the AFCAS-trial-
More informationA case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD
A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD NAVAL HOSPITAL OF ATHENS case presentation Female, 81yo Hx: diabetes mellitus, hypertension, chronic anaemia presented
More information